Open Orphan shares continue to surge after confirming ‘advanced’ COVID-19 vaccine challenge trials

The share price of Open Orphan (LON: ORPH) continued its rapid surge on Friday after the pharmaceutical company issued a brief update on the proposed COVID-19 vaccine challenger trials.

With shares in ORPH nearly doubling in the past month to 28p, the company has rewarded investors with a 460% return in the year-to-date.

On Friday, ORPH shares gained nearly 7 percent after it confirmed advanced talks with the UK government over COVID-19 vaccine challenge trials:

“Further to our announcement of 24 September 2020 and further media comment the Company confirms that it remains in advanced negotiations with the UK Government and other partners for a Coronavirus challenge study in the UK. No contract has been signed and the Company will update the market in due course as appropriate.”

Any proposed human challenge trials would have to be approved by the Medicines and Healthcare products Regulatory Agency.

Let's Talk

ODX - guess on how much revenue c …I guess we'll find out more later this month as they are upda … Read More
ISA or share dealing accountJust start with an ISA. If you get past ¬£10k in trading then rethi … Read More
Can you speak to ZOE management n …Hopefuly you are taking more requests Surface Transforms¬† Read More
People who trash AIM...Amen. There's some people who think they are really smart, bu … Read More
Christmas is saved? Boris Johnson … The government is reportedly planning to conduct 3 million COVID- … Read More
Hey, profit awaits! Free Sharebuyers Newsletter

Receive the hottest share tips and must-know investing information you can profit from.